MNPR Stock Price, Monopar Therapeutics Inc Quote, Chart

Market Summary

USD0.61-0.01

Delayed

-1.61%

MNPR Stock Price

View Fullscreen

MNPR RSI Chart

MNPR Valuation

Market Cap

10.7M

Price/Earnings (Trailing)

-1.4

Price/Free Cashflow

-1.47

MNPR Price/Sales (Trailing)

MNPR Profitability

Return on Equity

-101.76%

Return on Assets

-85.37%

Free Cashflow Yield

-67.91%

MNPR Fundamentals

MNPR Revenue

MNPR Earnings

Earnings (TTM)

-7.6M

Earnings Growth (Yr)

32.6%

Earnings Growth (Qtr)

9.53%

Breaking Down MNPR Revenue

Last 7 days

-9.0%

Last 30 days

-6.1%

Last 90 days

79.4%

Trailing 12 Months

-30.7%

How does MNPR drawdown profile look like?

MNPR Financial Health

Current Ratio

5.07

MNPR Investor Care

Shares Dilution (1Y)

32.23%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Monopar Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	robinson chandler	sold (taxes)	-4,884	0.681	-7,172	chief executive officer
Mar 31, 2024	tsuchimoto kim r	acquired	-	-	9,956	chief financial officer
Mar 31, 2024	robinson chandler	acquired	-	-	24,474	chief executive officer
Mar 31, 2024	tsuchimoto kim r	sold (taxes)	-2,779	0.681	-4,082	chief financial officer
Mar 31, 2024	cittadine andrew	acquired	-	-	8,952	chief operating officer
Mar 31, 2024	cittadine andrew	sold (taxes)	-2,109	0.681	-3,098	chief operating officer
Jan 01, 2024	robinson chandler	acquired	-	-	6,724	chief executive officer
Jan 01, 2024	tsuchimoto kim r	sold (taxes)	-171	0.3402	-505	chief financial officer
Jan 01, 2024	tsuchimoto kim r	acquired	-	-	1,231	chief financial officer
Jan 01, 2024	robinson chandler	sold (taxes)	-791	0.3402	-2,327	chief executive officer

Which funds bought or sold MNPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	273	545	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	340	340	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	108	108	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	117	4,120	5,350	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	555	121,035	131,011	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-4,866	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 14, 2024	NewEdge Advisors, LLC	new	-	2,043	2,043	-%
May 13, 2024	HRT FINANCIAL LP	new	-	21,000	21,000	-%
May 13, 2024	FMR LLC	new	-	3,746	3,746	-%

Are Funds Buying or Selling MNPR?

Are funds buying MNPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNPR

No. of Funds

Unveiling Monopar Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jun 02, 2023	klunzinger jeffrey r.	5.24%	692,800	SC 13G

Recent SEC filings of Monopar Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 16, 2024	8-K	Current Report
Apr 10, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Monopar Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Monopar Therapeutics Inc News

Latest updates

Monopar Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)		(In Thousands)
Description	(%) Q/Q	2023Q1	2021Q1
Revenue	-92.6%	807	10,925
Operating Expenses	33.3%	2,525	1,895
S&GA Expenses	26.7%	872	688
R&D Expenses	37.0%	1,653	1,207
Interest Expenses	746.0%	90.00	11.00
Net Income	-29.2%	-2,434	-1,884
Free Cashflow	-Infinity%	-2,271	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	21.3%	9.00	7.00	9.00	10.00	12.00	13.00	14.00	17.00	18.00	21.00	23.00	24.00	26.00	17.00	18.00	13.00	13.00	13.00	5.00	6.00	6.00
Current Assets	21.5%	9.00	7.00	9.00	10.00	12.00	13.00	14.00	17.00	18.00	21.00	22.00	24.00	26.00	17.00	18.00	13.00	13.00	13.00	5.00	6.00	6.00
Cash Equivalents	7.5%	8.00	7.00	6.00	7.00	6.00	8.00	14.00	16.00	18.00	20.00	22.00	24.00	26.00	17.00	18.00	13.00	13.00	13.00	4.00	5.00	6.00
Liabilities	-18.3%	1.00	2.00	2.00	3.00	3.00	3.00	2.00	2.00	1.00	2.00	1.00	1.00	-	1.00	1.00	1.00	0.00	1.00	0.00	0.00	1.00
Current Liabilities	-100.0%	-	2.00	2.00	3.00	3.00	3.00	2.00	2.00	1.00	2.00	-	-	1.00	1.00	1.00	1.00	0.00	1.00	0.00	0.00	1.00
Shareholder's Equity	33.8%	7.00	6.00	7.00	8.00	9.00	10.00	13.00	15.00	17.00	19.00	21.00	23.00	25.00	16.00	17.00	12.00	12.00	13.00	5.00	5.00	6.00
Retained Earnings	-2.6%	-61.80	-60.21	-58.40	-56.44	-54.24	-51.80	-48.91	-46.51	-43.75	-41.29	-38.61	-36.15	-34.07	-32.19	-30.06	-28.42	-26.97	-25.88	-24.67	0.00	-23.03
Additional Paid-In Capital	5.3%	69.00	66.00	65.00	64.00	63.00	62.00	61.00	61.00	61.00	60.00	60.00	59.00	59.00	48.00	48.00	41.00	39.00	39.00	29.00	29.00	29.00
Shares Outstanding	17.3%	17.00	15.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5.00	-	-	-	10.00	-	-	-	25.00	-	-	-	17.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-7.1%	-1,655	-1,545	-1,939	-2,101	-2,271	-1,301	-2,148	-1,310	-2,467	-2,031	-1,941	-1,406	-1,938	-1,240	-1,300	-995	-1,125	-668	-613	-739	-995
Share Based Compensation	-30.7%	329	474	474	473	476	393	391	357	500	350	392	358	368	331	284	367	338	277	243	258	234
Cashflow From Investing	-133.1%	-983	2,970	-13.05	2,954	-983	-4,918	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	851.1%	3,182	335	247	641	805	139	-23.74	-65.46	-16.67	-7.77	-9.98	-24.00	10,921	-7.14	6,735	946	508	9,387	-13.28	-12.32	-13.85

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MNPR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 966,110	$ 1,653,369
General and administrative	757,281	871,675
Total operating expenses	1,723,391	2,525,044
Loss from operations	(1,723,391)	(2,525,044)
Interest income	82,165	90,488
Net loss	(1,641,226)	(2,434,556)
Other comprehensive income (loss):
Foreign currency translation loss	(835)	(10,800)
Unrealized gain on investments	19,198	33,645
Comprehensive loss	$ (1,622,863)	$ (2,411,711)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.1)	$ (0.19)
Weighted average shares outstanding:
Basic and diluted (in shares)	15,979,816	13,105,831

MNPR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,807,579	$ 7,266,080
Investments	985,730	0
Other current assets	118,987	66,433
Total current assets	8,912,296	7,332,513
Operating lease right-of-use asset	0	12,646
Total assets	8,912,296	7,345,159
Current liabilities:
Accounts payable, accrued expenses and other current liabilities	1,435,160	1,757,393
Total current liabilities and total liabilities	1,435,160	1,757,393
Commitments and contingencies (Note 8)
Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 17,484,175 and 14,904,497 shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively	17,484	14,905
Additional paid-in capital	69,302,864	65,793,210
Accumulated other comprehensive income (loss)	4,231	(14,132)
Accumulated deficit	(61,847,443)	(60,206,217)
Total stockholders’ equity	7,477,136	5,587,766
Total liabilities and stockholders’ equity	$ 8,912,296	$ 7,345,159

About Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaÃƒÂ±ol de InvestigaciÃƒÂ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

CEO	Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
WEBSITE	monopartx.com
INDUSTRY	Biotechnology
EMPLOYEES	11

Monopar Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Monopar Therapeutics Inc? What does MNPR stand for in stocks?

MNPR is the stock ticker symbol of Monopar Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Monopar Therapeutics Inc (MNPR)?

As of Fri May 17 2024, market cap of Monopar Therapeutics Inc is 10.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNPR stock?

You can check MNPR's fair value in chart for subscribers.

What is the fair value of MNPR stock?

You can check MNPR's fair value in chart for subscribers. The fair value of Monopar Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Monopar Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Monopar Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MNPR is over valued or under valued. Whether Monopar Therapeutics Inc is cheap or expensive depends on the assumptions which impact Monopar Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNPR.